Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.78 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.59 |
| ▸ | MFN2 | O95140 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22315366 | 0.88 | EPHX1 (0.76) | EPHX1EPHX2NPC1TP53TSHR | |
| SCHEMBL22289723 | 0.88 | EPHX1 (0.76) | EPHX1EPHX2NPC1TP53TSHR | |
| SCHEMBL12196139 | 0.88 | EPHX1 (1.00) | EPHX1EPHX2NPC1TP53TSHR | |
| SCHEMBL17117397 | 0.85 | EPHX1 (0.76) | EPHX1EPHX2NPC1TP53TSHR | |
| SCHEMBL22289764 | 0.85 | EPHX1 (0.76) | EPHX1EPHX2NPC1TP53TSHR | |
| SCHEMBL22315780 | 0.85 | EPHX1 (0.71) | EPHX1EPHX2NPC1TP53TSHR | |
| SCHEMBL4955112 | 0.83 | EPHX1 (1.00) | EPHX1EPHX2NPC1TP53TSHR | |
| SCHEMBL22316228 | 0.83 | EPHX1 (0.73) | EPHX1EPHX2NPC1TP53TSHR | |
| SCHEMBL30645033 | 0.81 | EPHX1 (0.77) | EPHX1EPHX2TSHRRAB9AMFN2 | |
| SCHEMBL22289395 | 0.80 | EPHX1 (0.58) | EPHX1EPHX2NPC1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12409157-B2 | Mitofusin activators and methods of use thereof | DORN, GERALD W., II, DR. | 2025-09-09 | — | — | US | disclosed |
| US-20240082180-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | DORN, GERALD W., II, DR. | 2024-03-14 | — | — | US | disclosed |
| US-11141390-B2 | Mitofusin activators and methods of use thereof | MITOCHONDRIA EMOTION, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11141390-B2 | Mitofusin activators and methods of use thereof | MITOCHONDRIA EMOTION, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210251927-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210251927-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-11026904-B2 | Mitofusin activators and methods of use thereof | MITOCHONDRIA EMOTION, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11026904-B2 | Mitofusin activators and methods of use thereof | MITOCHONDRIA EMOTION, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210046028-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210046028-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200345669-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200345669-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| WO-2020159576-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082180-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, FIS1, TFB2M | EPHX1 4069/4885EPHX2 4205/4885NPC1 1003/4885 |
| US-11141390-B2 | Mitofusin activators and methods of use thereof | MFN2, FIS1, TFB2M | EPHX1 4069/4885EPHX2 4205/4885NPC1 1003/4885 |
| US-11026904-B2 | Mitofusin activators and methods of use thereof | MFN2, FIS1, TFB2M | EPHX1 4069/4885EPHX2 4205/4885NPC1 1003/4885 |
| US-20200345669-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, FIS1, TFB2M | EPHX1 4069/4885EPHX2 4205/4885NPC1 1003/4885 |
| US-20210251927-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, FIS1, TFB2M | EPHX1 4069/4885EPHX2 4205/4885NPC1 1003/4885 |
| US-12409157-B2 | Mitofusin activators and methods of use thereof | MFN2, FIS1, TFB2M | EPHX1 4069/4885EPHX2 4205/4885NPC1 1003/4885 |
| US-20210046028-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, FIS1, TFB2M | EPHX1 4069/4885EPHX2 4205/4885NPC1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.